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Background. We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients 
infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies per-
formed in 2002, 2009, and 2015.
Methods. The study was performed in 43 centers during October–November 2016. The sample was estimated for an accuracy 
of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-act-
ing antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV 
transmissibility.
Results. The reference population and the sample size were 38 904 and 1588 patients, respectively. The prevalence of HCV-Abs 
in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence 
of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treat-
ment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related 
cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared 
HCV after anti-HCV therapy.
Conclusions. Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and 
screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the bur-
den of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.
Keywords. coinfection/*epidemiology; hepatitis C/drug therapy/*epidemiology; HIV infection/*epidemiology; Spain/
epidemiology.
 
Coinfection by hepatitis C virus (HCV) is one of the most com-
mon comorbidities in patients infected by the human immu-
nodeficiency virus (HIV), particularly in areas in which HIV 
infection has been acquired mainly through injection drug use 
(IDU) [1, 2]. However, since 2000, a substantial increase in the 
number of new HCV infections has been reported among men 
who have sex with men (MSM) involved in high-risk practices, 
particularly in metropolitan areas of Northern Europe, the 
United States of America, and Australia [3–5].
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In the last few years, the introduction of direct-acting anti-
viral agents (DAAs) has revolutionized the treatment of HCV 
[6] and has provided new opportunities for treatment of coin-
fected individuals, a population considered to be difficult to 
treat in the interferon plus ribavirin era.
In countries like Spain, where sexually acquired HCV infec-
tion has contributed little to the burden of HIV/HCV coinfec-
tion to date, the prevalence of HCV antibodies and active HCV 
infection among HIV-infected individuals has decreased sub-
stantially over the years owing to several factors, including the 
decline in IDU as a mechanism of transmission of HIV infection, 
the greater mortality in HIV/HCV-coinfected patients than in 
HIV-monoinfected patients, and the increased uptake of anti-
HCV treatment [7, 8]. All these factors provide strong arguments 
in favor of actively monitoring the burden of HIV/HCV coinfec-
tion. In this study, we present data from a nationwide prevalence 
study of HIV/HCV coinfection in Spain carried out in 2016.
SUBJECTS AND METHODS
The study was carried out by “Grupo de Estudio del SIDA” 
(AIDS Study Group; GeSIDA) of the “Sociedad Española 
de Enfermedades Infecciosas y Microbiologıa Clınica” 
([SEIMC] Spanish Society of Infectious Diseases and Clinical 
Microbiology) between October 1, 2016 and December 30, 
2016 after a methodology similar to that used in 3 previous 
studies performed in 2002, 2009, and 2015 and reported in full 
elsewhere [7, 9, 10].
Design and Sample Size Considerations
This cross-sectional study was performed in 43 hospitals 
throughout Spain. The reference population was all HIV-infected 
patients in active follow-up in the participating centers. Active 
follow-up was defined as at least 1 visit to the center in the previ-
ous 12 months. Before the study was initiated, the total number of 
patients in active follow-up at the participating centers was 38 904 
and the prevalence of active HCV infection was 22.1%, accord-
ing to the most recent survey carried out by GeSIDA in 2015 [7]. 
Based on these figures, a confidence level of 95%, a design effect 
of 1.0, and an accuracy for the sample size of 2.0%, we estimated 
that a sample of at least 1588 patients was needed.
Patient Selection
The number of patients to be included at each center was deter-
mined by proportional allocation, and patients were selected by 
simple random sampling (full details in [7]). The Institutional 
Ethics Committee of Hospital General Universitario Gregorio 
Marañón approved the study and waived the requirement for writ-
ten informed consent, because the study was based on anonym-
ous routine clinical data intended for scientific publication.
Variables and Statistical Analysis
We collected demographic data, HIV transmission category, 
Centers for Diseases Control and Prevention (CDC) disease 
category, current CD4+ T-cell counts, current HIV-ribonucleic 
acid (RNA), whether patients were on combination antiretro-
viral therapy (cART), and the regimen used. We also inquired 
about the presence of hepatitis B virus surface antigen (HBsAg), 
the presence of HCV antibodies, and—if applicable—the pres-
ence of HCV-RNA. In patients with HCV antibodies, infor-
mation was also obtained about anti-HCV therapy and—if 
applicable—the regimens used and their outcomes. Patients 
receiving anti-HCV therapy at the time the study was per-
formed were considered to be HCV-RNA positive. In the case 
of patients with HCV antibodies and negative HCV-RNA, we 
inquired whether this was due to spontaneous clearance or 
to anti-HCV treatment. In patients with HCV antibodies and 
who were HCV-RNA positive, we collected HCV genotype and 
subtype. In patients who were positive for HCV-RNA and/or 
HBsAg, transient elastography results and the date the proce-
dure was performed were recorded.
The presence of liver cirrhosis was investigated in all patients, 
as was the method of diagnosis, namely, liver biopsy, transient 
elastography (liver stiffness  >12.5 kPa), or clinical/biological 
findings. Patients with prior or current episodes of ascites, 
hepatic encephalopathy, or variceal bleeding were considered 
to have decompensated liver disease. In patients with cirrho-
sis, current Child-Pugh and Model for End-Stage Liver Disease 
(MELD) scores were recorded. We also recorded whether 
patients had been diagnosed with hepatocellular carcinoma and 
whether they had undergone liver transplantation. We calcu-
lated anti-HCV treatment uptake, defined as the percentage of 
patients with current or past chronic HCV infection exposed to 
anti-HCV therapy.
All the information was entered into a shared database at 
each institution using an online electronic case report form. 
A descriptive analysis was carried out using frequency tables for 
categorical variables and mean and standard deviation (SD) or 
median and interquartile range (IQR) for normally and nonnor-
mally distributed continuous variables. We used the χ2 test of 
independence to detect significant differences in categorical var-
iables and the t test or the nonparametric Mann-Whitney test for 
differences in normally or nonnormally distributed continuous 
variables, respectively. All statistical analyses were performed 
using Stata, version 14.0 (StataCorp, College Station, TX).
RESULTS
A total of 43 centers participated in the study. The reference 
population was 38 904 HIV-infected patients, and the sample 
size was 1588 patients.
Patients’ Characteristics
The characteristics of the 1588 patients included in the study are 
summarized in Table 1. No significant differences were found for 
sex between HCV-seronegative and HCV-seropositive patients; 
however, the latter were 4 years older than the former, on aver-
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HCV-seropositive patients than among HCV-seronegative 
patients, whereas the frequency of both transmission via het-
erosexual relations and sexual relations between MSM was 
significantly higher among HCV-seronegative than among 
HCV-seropositive patients. Hepatitis B virus surface antigen 
positivity was more frequent in HCV-seronegative patients than 
in HCV-seropositive patients (4.4% vs 2.5%; P < .019).
More HCV-seropositive patients were in CDC category C 
than HCV-seronegative patients (30.3% vs 22.8%; P  <  .001). 
Overall, 96.7% of patients were on cART. In comparison with 
HCV-seronegative patients, a small but significantly higher 
proportion of HCV-seropositive patients were on cART (98.2% 
vs 95.8%, respectively; P  =  .014). In comparison with HCV-
seronegative patients, a significantly lower proportion of HCV-
seropositive patients were receiving a first-line cART regimen 
(22.9% vs 7.2%, respectively; P  <  .001). The proportion of 
patients with an HIV-RNA load <50 copies/mL was 89.5% over-
all and 92.2% in patients receiving cART. Among the latter, no 
significant differences were found between HCV-seropositive 
and HCV-seronegative patients. In the full data set, statistically 
significantly lower CD4+ T-cell counts were found among HCV-
seropositive patients than among HCV-seronegative patients 
(671 vs 654 cells/µL; P = .045) and in patients on cART (678 vs 
659 cells/µL; P = .039), although the differences were small.
Prevalence of Anti-Hepatitis C Virus (HCV) Antibodies and Active HCV 
Infection
Hepatitis C virus serostatus was known in 1585 (99.8%) patients, 
548 of whom were HCV seropositive. Of these 548 patients, 186 
were HCV-RNA positive, 292 were HCV-RNA negative after 
sustained viral response after anti-HCV therapy, 68 cleared 
HCV spontaneously, and HCV-RNA results were unknown in 2.  
The prevalence of anti-HCV antibodies was therefore 34.6% 
among tested patients (548 of 1585 patients whose serostatus 
was known), and the prevalence of active HCV infection was 
11.7% (186 of 1583 patients with known HCV serostatus and 
with known HCV-RNA among those with HCV antibodies).
Comparison With Previous Prevalence Studies
We compared the results of this study with those of 3 national 
studies carried out by GeSIDA in 2002, 2009, and 2015 in a sim-
ilar number of centers across the same geographical areas of 
Spain [7, 9, 10]. A summary of participating centers, reference 
population, and sample size of the studies performed in 2002, 
2009, 2015, and 2016 is shown in Table 2.
The main HIV transmission categories among HIV-infected 
individuals in the 4 prevalence studies are shown in Figure 1. 
From 2002 to 2015, there was a significant decrease in the pro-
portion of IDU (from 55.2% to 30.7%) and a significant increase 
in the proportion of MSM (from 17.2% to 35.1%). However, no 
significant changes were observed from 2015 to 2016.
The prevalence of anti-HCV antibodies and the prevalence of 
active HCV infection in the 4 studies are shown in Figure 2. The 
prevalence of anti-HCV antibodies decreased significantly from 
60.8% in 2002 to 37.7% in 2015 (P trend <.001) and remained 
almost unchanged in 2016 (34.6%). In addition, the prevalence 
of active HCV infection decreased significantly from 54.0% in 
2002 to 11.7% in 2016 (P trend <.001). Of note, a 47.1% reduc-
tion in the prevalence of active HCV infection was observed 
from 2015 to 2016. In contrast, the decrease in the prevalence 
of active HCV infection was 37.0% in the 8-year period from 
2002 to 2009 and 35.0% in the 7-year period from 2009 to 2015.
Anti-HCV treatment uptake in the 4 prevalence studies is 
shown in Figure  3. The proportion of patients with current 
or past chronic HCV infection exposed to anti-HCV therapy 
increased significantly from 23.0% in 2002 to 74.7% in 2016.
Characteristics of Patients With Active Hepatitis C Virus Infection
The characteristics of the 186 patients with active HCV infec-
tion are summarized in Table  3. A  total of 121 (65.1%) were 
naive for anti-HCV therapy, and 41 (22.0%) were receiving oral 
DAA therapy during the study. Two patients (1.1%) with active 
HCV infection had reinfections after sustained viral response 
with pegylated interferon plus ribavirin. The HCV genotype 
was unknown in 10 patients (5.4%). Among the remaining 
176 patients, the most common infecting genotypes were 1a 
(46.6%), 4 (22.2%), 3 (15.9%), and 1b (13.6%). Transient elas-
tography was performed in 150 patients (80.6%) a median of 
10 months before data were collected. The median liver stiffness 
value was 6.6 kPa. The distribution of liver stiffness by cutoff 
was as follows: <7.1 kPa (absent or mild liver fibrosis), 58.0%; 
>9.5 kPa (advanced fibrosis), 23.3%; and >12.5 kPa (cirrhosis), 
16.0% [11]. In addition, the fibrosis-4 (FIB-4) score was avail-
able for 185 (99.5%) patients, 13.0% of whom had values ≥3.25 
(indicative of advanced liver fibrosis) [12].
The main features of liver cirrhosis in patients with active HCV 
infection and in those who cleared HCV infection after anti-HCV 
therapy are summarized in Table 4. Liver cirrhosis was present in 
28 of 186 (15.0%) patients with active HCV infection and in 92 
of 292 (31.5%) patients who cleared HCV after anti-HCV ther-
apy. Thus, we can assume that of the 1588 HIV-infected patients 
included in the study, a diagnosis of HCV-related liver cirrhosis 
had been made at some point in 120 (7.6%) patients.
DISCUSSION
This study showed that at the end of 2016, the prevalence of 
active HCV infection among HIV-infected individuals in Spain 
was 11.7%. This represents an approximately 50% decrease 
in comparison with the prevalence found in 2015. This sharp 
decrease occurred concurrently with increased access to oral 
DAAs for treatment of HCV. The study also showed that 
approximately 7.6% of all HIV-infected individuals in Spain 
had HCV-related cirrhosis, a condition that was twice as com-
mon in coinfected patients with a sustained viral response than 
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Male sex, n (%) 3 (100.0) 140 (75.3) 233 (79.8) 41 (60.3) 1 (50.0) 415 (75.7) 805 (77.6) .39 1223 (77.0)
Age years, mean (SD) 51 (4) 50 (7) 52 (6) 51 (8) 50 (5) 51 (7) 47 (12) <.001 49 (11)
HIV transmission category, 
n (%)
 Injection drug use 0 140 (75.3) 231 (79.1) 44 (64.7) 2 (100.0) 417 (76.1) 53 (5.1) <.001 470 (29.6)
 Heterosexual 0 22 (11.8) 22 (7.5) 14 (20.6) 0 58 (10.6) 318 (30.7) 376 (23.7)
 Men who have sex with 
men
3 (100.0) 12 (6.4) 14 (4.8) 4 (5.9) 0 30 (5.5) 523 (50.4) 556 (35.0)
 Contaminated blood 
products
0 2 (1.1) 2 (0.7) 0 0 4 (0.7) 1 (0.1) 5 (0.3)
 Mother-to-child 
transmission
0 2 (1.1) 0 1 (1.5) 0 3 (0.5) 8 (0.8) 11 (0.7)
 Other 0 8 (4.3) 23 (7.9) 5 (7.3) 0 36 (6.6) 134 (12.9) 170 (10.7)
HBsAg, n (%)
 Negative 1 (33.3) 171 (91.9) 278 (95.2) 64 (94.1) 2 (100.0) 515 (94.0) 973 (93.8) .019 1489 (93.8)
 Positive 0 5 (2.7) 5 (1.7) 4 (5.9) 0 14 (2.5) 46 (4.4) 60 (3.8)
 Unknown 2 (66.7) 10 (5.4) 9 (3.1) 0 0 19 (3.5) 18 (1.7) 39 (2.5)
CDC clinical category C, n 
(%)
0 54 (29.0) 92 (31.5) 20 (29.4) 0 166 (30.3) 236 (22.8) .001 402 (25.3)
cART, n (%) 3 (100.0) 181 (97.3) 289 (99.0) 66 (97.1) 2 (100.0) 538 (98.2) 994 (95.8) .014 1535 (96.7)
Type of cART regimen, n (%)
 2 NRTI + 1 NNRTI 1 (33.3) 45 (24.9) 75 (25.9) 16 (24.2) 0 136 (25.2) 376 (37.8) <.001 513 (33.4)
 2 NRTI + 1 PI 0 32 (17.7) 31 (10.7) 9 (13.6) 1 (50.0) 74 (13.7) 118 (11.9) 191 (12.4)
 2 NRTI + 1 integrase 
inhibitor
2 (66.7) 61 (33.7) 101 (34.9) 21 (31.8) 0 183 (33.9) 312 (31.4) 497 (32.4)
 PI-based monotherapy 0 13 (7.2) 19 (6.6) 4 (6.1) 0 36 (6.7) 49 (4.9) 85 (5.5)
 PI-based bitherapy 0 15 (8.3) 30 (10.4) 8 (12.1) 0 53 (9.8) 56 (5.6) 109 (7.1)
 Other 0 15 (8.3) 33 (11.4) 8 (12.1) 1 (50.0) 57 (10.6) 83 (8.3) 140 (9.1)
Category of cART regimen, 
n (%)
 First-line therapy 0 15 (8.3) 17 (5.9) 7 (10.6) 0 39 (7.2) 228 (22.9) <.001 267 (17.4)
 Switch unrelated to toxicity/ 
failure
1 (33.3) 100 (55.2) 168 (58.1) 28 (42.4) 1 (50.0) 298 (55.3) 436 (43.9) 734 (47.8)
 Switch after failure 0 24 (13.3) 19 (6.6) 8 (12.1) 1 (50.0) 52 (9.6) 60 (6.0) 112 (7.3)
 Switch after toxicity 2 (66.7) 40 (22.1) 80 (27.7) 22 (33.3) 0 142 (26.3) 240 (24.1) 384 (25.0)
 Unknown 0 2 (1.1) 5 (1.7) 1 (1.5) 0 8 (1.5) 30 (3.0) 38 (2.5)
HIV-RNA copies/mL, n (%)
 All patients
 <50 3 (100.0) 158 (84.9) 276 (94.5) 57 (83.8) 2 (100.0) 493 (90.0) 926 (89.3) .15 1422 (89.5)
 50–200 0 7 (3.8) 9 (3.1) 7 (10.3) 0 23 (4.2) 30 (2.9) 53 (3.3)
 >200 0 21 (11.3) 7 (2.4) 4 (5.9) 0 32 (5.8) 81 (7.8) 113 (7.1)
 Patients on cART
 <50 3 (100.0) 157 (86.7) 273 (94.5) 56 (84.8) 2 (100.0) 488 (90.7) 924 (93.0) .28 1415 (92.2)
 50–200 0 7 (3.9) 9 (3.1) 7 (10.6) 0 23 (4.3) 30 (3.0) 53 (3.4)
 >200 0 17 (9.4) 7 (2.4) 3 (4.5) 0 27 (5.0) 40 (4.0) 67 (4.4)
CD4+ T cells/µL, median (IQR)
 All patients 744 (522–805) 600 (372–826) 680 (455–909) 764 (438–925) 205 (185–225) 654 (429–882) 671 (492–904) .045 670 (470–895)
 Patients on cART 744 (522–805) 605 (390–826) 684 (455–911) 764 (448–925) 205 (185–225) 659 (431–886) 678 (495–910) .039 670 (472–897)
Abbreviations: cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus; HIV, human immu-
nodeficiency virus; IQR, interquartile range; PI, protease inhibitor; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; RNA, ribonucleic 
acid; SD, standard deviation.
aP values for the comparisons between HCV-positive patients (n = 548) and HCV-negative patients (n = 1037) derived from the χ2 test for independence for categorical variables and the t 
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The results of this study and previous GeSIDA studies [7, 9, 10] 
showed remarkable differences between the seroprevalence 
of HCV and the prevalence of active HCV infection among 
HIV-infected individuals in the 14-year period from 2002 and 
2016. The seroprevalence of HCV dropped sharply from 2002 
to 2015 but remained practically unchanged from 2015 to 2016 
(approximately 35%). However, the prevalence of active HCV 
infection decreased steadily from 54.0% in 2002 to 11.7% in 
2016. Of note, a 47% drop was observed from 2015 to 2016. This 
is a huge decrease if we consider that the decline in the preva-
lence of active HCV infection was 37.0% in the 8-year period 
from 2002 to 2009 and 35.0% in the 7-year period from 2009 to 
2015, respectively.
Several factors contributed to the declining trends in HCV 
seropositivity and active infection among HIV-infected indi-
viduals from 2002 to 2016. In the early years, the main factor 
was the reduction in the frequency of IDU as a mechanism 
of HIV transmission [13], together with the development of 
preventive drug programs [14]. The higher mortality rates in 
coinfected patients compared with HIV-monoinfected patients 
in this period also contributed to a decrease in the preva-
lence of HCV infection [15]. Over the last few years, however, 
the reduction of active HCV infection may be attributable to 
the increase in the frequency of anti-HCV treatment uptake, 
which went from 23.0% in 2002 to 59.3% and 74.7% in 2015 
and 2016, respectively. Of note, in the last 2  years, anti-HCV 
therapy in Spain consisted of DAA-based regimens. Under real-
life conditions, these regimens yielded high rates of sustained 
viral response that were similar to those of HCV-monoinfected 
patients and showed an excellent safety and tolerance profile, 
even in patients with end-stage liver disease [16, 17].
All of the above findings raise the question of whether the goal 
of elimination of HCV among HIV-infected individuals can be 
achieved in Spain in the short term. Elimination of an infec-
tion means the reduction to zero of the incidence of the disease 
caused by a specific agent in a defined geographical area because 
of deliberate efforts, requiring continued measures to prevent 
re-establishment of transmission [18]. If one considers that pre-
vention, screening, and universal access to treatment are essen-
tial for the elimination of HCV infection [19], Spain appears to 
be on the right track towards the achievement of this goal.
As previously mentioned, the preventive programs of the 
National Drug Strategy in Spain have proven effective for 
reduction of drug-related risk and harm [14]. These programs 
have included social and health services offering preventive 
educational interventions, overdose prevention activities, ster-
ile needles and syringes, testing for drug-related infections, vac-
cination against viral hepatitis, emergency care and assistance 
to injecting drug users (who do not usually have contact with 
support interventions), and a scaling up of opioid substitution 
treatment. The National Drug Strategy for the period 2017–24 
covers many illicit and licit substances [14]. As this and previ-
ous studies show, HCV infection acquired through sexual rela-
tions contributes little to the burden of coinfection in Spain and 
Table 2. Centers and Patients Included in the Nationwide HCV Prevalence 
Studies Carried out by GeSIDA in 2002, 2009, 2015, and 2016
Variable 2002 2009 2015 2016
Participating centers 39 43 41 43
Reference population 31 800 29 559 35 791 38 904
Sample size 1260 1458 1867 1588
Tested for HCV antibodies 99.5% 99.8% 98.7% 99.8%
Reference 9 10 7 Current study
Abbreviations: GeSIDA, Grupo de Estudio del SIDA; HCV, hepatitis C virus; IQR, interquar-
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Figure 1. Principal human immunodeficiency virus transmission categories in the 
cross-sectional studies carried out by Grupo de Estudio del SIDA in 2002, 2009, 





















*,** P trend < .001
HCV Ab+
HCV RNA+









Figure  2. Prevalence of hepatitis C virus (HCV) seropositivity and active HCV 
infection in the cross-sectional studies carried out by Grupo de Estudio del SIDA in 
2002, 2009, 2015, and 2016. HCV Ab+, presence of antibodies against HCV; HCV-
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remains restricted to specific areas of Madrid and Barcelona 
[20, 21]. However, prevention activities should also be under-
taken to reduce high-risk behavior among both HIV-infected 
and non-HIV-infected MSM who engage in high-risk practices 
for sexual transmission of HCV [5].
Hepatitis C virus screening practices among HIV-infected 
individuals appear to be of a high standard according to the 
results of the 4 prevalence studies performed over the last 
14  years, which have consistently shown that 99% of HIV-
infected individuals are tested for HCV antibodies [7]. However, 
it is important to perform regular screening for HCV among 
HIV-infected people who engage in high-risk practices. In add-
ition, testing should be considered in migrants from regions 
with a high prevalence of HCV, such as sub-Saharan Africa and 
Eastern Europe [22, 23].
As for universal access to therapy, a total of 63 075 patients 
with HCV—20% of whom were coinfected—were treated with 
all oral DAA-based regimens in Spain from January 1, 2015 to 
September 31, 2016 [24]. During the first months, access to 
therapy was prioritized for patients with advanced liver fibro-
sis or cirrhosis; however, in 2015, in most autonomous regions 
of Spain, access to DAA therapy was available for patients with 
significant fibrosis (METAVIR F ≥2 in liver biopsy or equivalent 
by transient elastography). Furthermore, irrespective of liver 
fibrosis stage, DAA-based therapy could also be administered to 
patients with clinically significant extrahepatic manifestations 
of HCV (such as symptomatic mixed cryoglobulinemia) and 
to patients at risk of transmitting HCV (active injection drug 
users, MSM with high-risk sexual practices for acquiring HCV, 
and women of childbearing age who wish to become pregnant). 
In June 2017, the Spanish Ministry of Health committed to 
providing access to DAA-based therapy for all individuals with 
HCV, irrespective of the stage of fibrosis [25].
An important observation in this study was the finding that 
almost 8% of all HIV-infected individuals had been diagnosed 
at some time with HCV-related liver cirrhosis. Of note, cir-
rhosis was more common in patients who had achieved a sus-
tained viral response than in those with active HCV infection. 
This finding underscores the fact that despite the well known 
benefits of eradicating HCV among coinfected individuals in 
terms of reduced morbidity and mortality [26], there persists 
a residual risk for liver-related events, especially hepatocellular 
carcinoma, in patients with cirrhosis in whom HCV has been 
eradicated [27, 28]. Therefore, even if we achieve the proba-
ble and desired goal of eliminating HCV among HIV-infected 
individuals, the burden of HCV-related cirrhosis will remain 
Table 3. Characteristics of Liver Disease in the 186 Patients Who Were 
HCV-RNA Positive
Characteristic N = 186
Anti-HCV Therapy, n (%)a
 Never 121 (65.1)
 Ongoingb 41 (22.0)
 In the past 34 (18.3)
 Null response or partial response 26 (76.5)
 Relapse 1 (2.9)
 Abandonment or interruption due to adverse events 5 (14.7)
 Sustained viral response 2 (5.9)
HCV Genotype, n (%)
 Unknown 10 (5.4)
 Known 176 (94.6)
 1a 82 (46.6)
 4 39 (22.2)
 1b 24 (13.6)
 3 28 (15.9)
 2 3 (1.7)
 Mixed 0
TE Results
 Patients with TE, n (%) 150 (80.6)
 Months from TE to study date, median (IQR) 10.0 (5.6–21.9)
 TE value–kPa, median (IQR) 6.6 (5.4–9.1)
 TE distribution according to cutoff values–kPa, n (%)
 <7.1 87 (58.0)
 7.1–9.5 28 (18.7)
 9.6–12.5 11 (7.3)
 >12.5 24 (16.0)
FIB-4 Index Results
 Patients with FIB-4, n (%) 185 (99.5)
 FIB-4 value, median (IQR) 1.5 (1.1–2.2)
 FIB-4 Distribution According to Cutoff Values, n (%)
 ≤1 39 (21.1)
 1–3.25 122 (65.9)
 ≥3.25 24 (13.0)
Abbreviations: DAA, direct-acting antiviral agent; FIB-4, fibrosis 4; HCV, hepatitis C virus; 
IQR, interquartile range; RNA, ribonucleic acid; TE, transient elastography.
aThe number of patients in the “never”, “ongoing”, and “in the past” categories total more 
than 186 because the groups overlap. Of the 186 patients, 121 were naive for anti-HCV 
therapy, 31 are currently receiving therapy but had not received it previously, 24 are not 
currently receiving therapy but had received it in the past, and 10 are currently receiving 
treatment and received it in the past.
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Figure  3. Anti-hepatitis C virus (HCV) treatment uptake in the cross-sectional 
studies carried out by Grupo de Estudio del SIDA in 2002, 2009, 2015, and 2016. 
Treatment uptake was defined as the proportion of patients with current or past 
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substantial. Considering the 130 000 to 160 000 people who live 
with HIV in Spain [29] and the 7.6% prevalence of HCV-related 
cirrhosis, between 9120 and 12 160 HIV-infected individuals 
with cirrhosis will need indefinite surveillance for hepatocellu-
lar carcinoma according to current recommendations [30, 31].
CONCLUSIONS
In conclusion, this study showed that at the end of 2016, the prev-
alence of active HCV infection among HIV-infected individuals 
in Spain was 11.7%, ie, an almost 50% decrease in comparison 
with the prevalence for 2015. This decrease was accompanied by a 
sharp increase in the uptake of oral DAAs against HCV. We believe 
that the universal treatment of HCV and the continued efforts in 
prevention and screening will make it possible to eliminate active 
HCV infection among HIV-infected individuals in Spain in the 
short term. However, despite the elimination of active HCV infec-
tion, HCV-related liver cirrhosis will continue to generate a signif-
icant burden among HIV-infected individuals in Spain.
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